Clay Siegall is the President, Chief Executive Officer as well as a member of the Board of Directors of Seattle Genetics.

This firm has been developing a diverse portfolio that includes clinical and preclinical product candidates. All of these are targeting various cancer as well as autoimmune indications. This company is a leader in antibody technologies. It is mainly known for its antibody-drug conjugate platform.

Dr. Clay Siegall has been responsible for guiding Seattle Genetics’ activities for raising capital. He has managed to secure over $330 million. This has been through public as well as private financings. It would also include the initial public offering of the company in 2001. Also, this company has been responsible for entering into multiple strategic collaborations. One of them is the exclusive worldwide collaboration agreement that was signed with Genentech for SGN-40. It is valued at over $860 million. There have been several other ADC collaborations. These would include those with Genentech, MedImmune, besides CuraGen, Bayer as well as Progenics. All these collaborations have managed to generate over $65 million. This has been since 2001.

Clay Siegall was working with the Bristol-Myers Squibb Pharmaceutical Research Institute. This was from 1991 to 1997. This was before co-founding Seattle Genetics. He was with the National Cancer Institute, National Institutes of Health from 1988 to 1991. Today Dr. Clay serves on the Board of Directors of Alder BioPharmaceuticals which is a private biotechnology company. He is also on the Board of Directors of the Washington Biotechnology and Biomedical Association (WBBA). Dr. Clay Siegall is on the Board of Governors of the Fred Hutchinson Cancer Research Business Alliance. He has received his Ph.D. in Genetics from George Washington University. He has earned a B.S. in Zoology from the University of Maryland.

All this has been a result of the expertise of Clay Siegall as well as his hard work in order to take his firm to new heights. He enjoys a good reputation, and hence he is on the Board of Directors of a large number of Associations. He is the guiding force behind his company.